跳至主要内容
临床试验/JPRN-UMIN000010370
JPRN-UMIN000010370已完成2 期

Phase II study on reduction of mucous membrane inflammation by the nutritional supplement Elental in concurrent chemoradiotherapy for head and neck squamous cell carcinoma - Reduction of mucous membrane inflammation by Elental in concurrent chemoradiotherapy

iigata University, Faculty of Medicine0 个研究点目标入组 50 人开始时间: 2013年4月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 75years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Past history of serious drug hypersensitivity 2) Presence of other cancer 3) Clinically problematic infectious disease 4) >1 complication that might affect treatment 5) Nonradical treatment indicated 6) Pregnant or nursing women and those with the possibility of pregnancy 7) Mental or neurologic disease that might affect participation 8) Abnormality in amino acid metabolism 9) Severe diabetes or possibility of glucose metabolism abnormality due to high-dose steroid treatment 10) Participation judged by physician to be inadvisable

研究者

发起方
iigata University, Faculty of Medicine

相似试验

Phase II study on reduction of mucous membrane... | 临床试验